JP2007522135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522135A5 JP2007522135A5 JP2006551595A JP2006551595A JP2007522135A5 JP 2007522135 A5 JP2007522135 A5 JP 2007522135A5 JP 2006551595 A JP2006551595 A JP 2006551595A JP 2006551595 A JP2006551595 A JP 2006551595A JP 2007522135 A5 JP2007522135 A5 JP 2007522135A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently
- subject
- electron withdrawing
- withdrawing group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 239000003550 marker Substances 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000005681 phospholamban Human genes 0.000 claims 4
- 108010059929 phospholamban Proteins 0.000 claims 4
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 claims 4
- 102000009023 sarcolipin Human genes 0.000 claims 4
- 108010088766 sarcolipin Proteins 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000002107 myocardial effect Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 claims 2
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical group [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims 2
- -1 perhaloalkyl Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 claims 1
- 206010011086 Coronary artery occlusion Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54068804P | 2004-01-30 | 2004-01-30 | |
| US63245604P | 2004-12-02 | 2004-12-02 | |
| PCT/US2005/003183 WO2005074598A2 (en) | 2004-01-30 | 2005-01-28 | Nitroxyl progenitor compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007522135A JP2007522135A (ja) | 2007-08-09 |
| JP2007522135A5 true JP2007522135A5 (enExample) | 2008-11-27 |
Family
ID=34841107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551595A Pending JP2007522135A (ja) | 2004-01-30 | 2005-01-28 | ニトロキシル前駆化合物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090281067A1 (enExample) |
| EP (1) | EP1718621A4 (enExample) |
| JP (1) | JP2007522135A (enExample) |
| AU (1) | AU2005209843B2 (enExample) |
| CA (1) | CA2554771A1 (enExample) |
| WO (1) | WO2005074598A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038947A1 (en) | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
| US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| WO2005074598A2 (en) | 2004-01-30 | 2005-08-18 | Johns Hopkins University | Nitroxyl progenitor compounds and methods of use |
| US20090298795A1 (en) * | 2005-06-23 | 2009-12-03 | The Johns Hopins University | Thiol-Sensitive Positive Inotropes |
| MX368352B (es) | 2006-03-17 | 2019-09-30 | Univ Johns Hopkins | Derivados de n-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiologicamente utiles. |
| BRPI0817562A2 (pt) | 2007-09-26 | 2017-05-02 | Cardioxyl Pharmaceuticals Inc | derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis |
| JP2011511079A (ja) * | 2008-02-08 | 2011-04-07 | メルク・シャープ・エンド・ドーム・コーポレイション | アンジオテンシンｉｉ受容体アンタゴニスト |
| US20110160200A1 (en) | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
| CA2782110A1 (en) | 2009-12-07 | 2011-06-16 | Johns Hopkins University | N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives |
| JP5832447B2 (ja) | 2009-12-07 | 2015-12-16 | ザ ジョンズ ホプキンス ユニバーシティ | ビスアシル化ヒドロキシルアミン誘導体 |
| CN103476744A (zh) * | 2011-01-19 | 2013-12-25 | 默沙东公司 | 二醇二氮烯鎓衍生物 |
| HK1200168A1 (en) | 2011-10-17 | 2015-07-31 | The Johns Hopkins University | Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors |
| PT2945620T (pt) | 2013-01-18 | 2018-02-21 | Cardioxyl Pharmaceuticals Inc | Dadores de nitroxilo com índice terapêutico melhorado |
| ES2734060T3 (es) | 2014-01-17 | 2019-12-04 | Cardioxyl Pharmaceuticals Inc | Donadores de nitroxilo de N-hidroximetanosulfonamida |
| US9682938B2 (en) | 2014-05-27 | 2017-06-20 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
| US9464061B2 (en) | 2014-05-27 | 2016-10-11 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives |
| EP3148983A1 (en) | 2014-05-27 | 2017-04-05 | The Johns Hopkins University | N-hydroxylamino-barbituric acid derivatives as nitroxyl donors |
| KR20180070672A (ko) | 2015-10-19 | 2018-06-26 | 카르디옥실 파마슈티칼스 인코포레이티드 | 니트록실 공여자로서의 n-히드록실술폰아미드 유도체 |
| JP6889704B2 (ja) | 2015-10-19 | 2021-06-18 | カルディオキシル ファーマシューティカルズ，インク． | ニトロキシルドナーとしてのピラゾロン誘導体 |
| KR20190070912A (ko) | 2016-07-28 | 2019-06-21 | 더 존스 홉킨스 유니버시티 | O-치환된 히드록삼산 |
| US11083704B2 (en) | 2017-01-03 | 2021-08-10 | Bristol-Myers Squibb Company | Method of administering nitroxyl donating compounds |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| WO2025043108A1 (en) | 2023-08-23 | 2025-02-27 | Bristol -Myers S Quibb Company | Co-crystals of nitroxyl donating compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
| US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
| US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| EP0605622B1 (en) * | 1991-09-24 | 1997-11-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US6200558B1 (en) * | 1993-09-14 | 2001-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5700830A (en) * | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| US6610660B1 (en) * | 1996-09-27 | 2003-08-26 | The United States Of America As Represented By The Department Of Health And Human Services | O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates |
| US5958427A (en) * | 1996-11-08 | 1999-09-28 | Salzman; Andrew L. | Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications |
| CA2293501A1 (en) * | 1997-07-03 | 1999-01-14 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Nitric oxide-releasing amidine-derived diazeniumdiolates, compositions and uses thereof |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US6638534B1 (en) | 1998-07-28 | 2003-10-28 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| US20050070509A1 (en) * | 2001-06-05 | 2005-03-31 | Dieter Zeller | Antimycotic agent |
| US7122529B2 (en) * | 2001-07-12 | 2006-10-17 | The Johns Hopkins University | Compounds that release nitric oxide at controlled rates upon photolysis |
| AU2003212534B2 (en) * | 2002-03-15 | 2010-01-21 | Biostatus Limited | Formulations of anthraquinone derivatives |
| WO2003080039A1 (en) * | 2002-03-21 | 2003-10-02 | The University Of Utah Research Foundation | In vivo use of glutathionone s-transferase activated nitric oxide donors |
| US20040038947A1 (en) * | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
| US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| US20050009789A1 (en) | 2003-05-13 | 2005-01-13 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service | Cyclooxygenase inhibition with nitroxyl |
| WO2005074598A2 (en) | 2004-01-30 | 2005-08-18 | Johns Hopkins University | Nitroxyl progenitor compounds and methods of use |
-
2005
- 2005-01-28 WO PCT/US2005/003183 patent/WO2005074598A2/en not_active Ceased
- 2005-01-28 JP JP2006551595A patent/JP2007522135A/ja active Pending
- 2005-01-28 EP EP05726388A patent/EP1718621A4/en not_active Withdrawn
- 2005-01-28 CA CA002554771A patent/CA2554771A1/en not_active Abandoned
- 2005-01-28 AU AU2005209843A patent/AU2005209843B2/en not_active Ceased
- 2005-01-28 US US10/587,644 patent/US20090281067A1/en not_active Abandoned
-
2014
- 2014-09-22 US US14/492,741 patent/US10273202B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007522135A5 (enExample) | ||
| JP2005528393A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2012529486A5 (enExample) | ||
| JP2006501295A5 (enExample) | ||
| JP2005521713A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2005539088A5 (enExample) | ||
| JP2009537559A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2005508337A5 (enExample) | ||
| JP2010248215A (ja) | 筋弛緩促進剤及び筋弛緩不全等の筋組織に係る疾病の治療薬 | |
| JP2010506919A5 (enExample) | ||
| WO2010069124A1 (zh) | 酰胺基噻唑衍生物及其制备方法和用途 | |
| JP2005526696A5 (enExample) | ||
| WO2003002554A1 (en) | Piperazine compounds | |
| JP2006524252A5 (enExample) | ||
| JP2020111571A5 (enExample) | ||
| US20250074878A1 (en) | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate | |
| JP2009040767A5 (enExample) | ||
| JP2010504321A5 (enExample) | ||
| JP2009537532A5 (enExample) | ||
| JP2007537287A5 (enExample) | ||
| JPWO2022221227A5 (enExample) |